NIFTY50 Archives - Page 2 of 13

APOLLOHOSP – Apollo Hospitals Enterprise – Q4 FY26 Earnings Call – 21-May-26

Apollo Hospitals’ topline growth hinges on new hospital ramp-up and digital scaling, while margins and bottomline depend on execution of HealthCo turnaround and capex discipline.

1–2 minutes

Also see: APOLLOHOSP – Apollo Hospitals Enterprise – Q4 FY26 Financial Results – 20-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Drivers: New hospitals break even by FY28 at 50–55% occupancy, digital breakeven in Q3 FY27 (incl. ESOP), and HealthCo margins reach 6.5%. Capex remains disciplined (INR 1,550 crore redeployable), and insurance revenue grows 15–20% YoY. Topline: 15–18% revenue CAGR; Bottomline: PAT CAGR ~25%; Margins: Healthcare Services EBITDA ~25.5%, HealthCo 6.5%.

ITC – ITC Limited – Q4 FY26 Investor Presentation – 21-May-26

ITC’s topline resilience hinges on FMCG-Others and NewGen channels, while bottomline and margins face structural pressure from taxation, illicit trade, and input costs.

1–2 minutes

Also see: ITC – ITC Limited – Q4 FY26 Financial Results – 21-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Tax hikes partially offset by pricing, but illicit trade captures 5-10% volume. Agri remains subdued due to geopolitical risks, while FMCG-Others sustains 10% revenue growth. EBITDA grows 5-7% YoY, with margins stable but compressed in Cigarettes/Paperboards.

BEL – Bharat Electronics – Q4 FY26 Earnings Call – 20-May-26

BEL/ Bharat Electronics’ topline resilience hinges on order execution (QRSAM/P-75I); margins remain robust (>28%) if indigenization offsets cost inflation, but cash flow conversion and working capital are key watchpoints.

1–2 minutes

Also see: BEL – Bharat Electronics – Q4 FY26 Financial Results – 19-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

QRSAM signs by Jun-2026, but P-75I slips to FY28; order inflow at ~INR 50,000 cr. EBITDA margins sustain at 28–29% (wage/semiconductor offsets indigenization gains). Revenue grows 15–16%, with cash conversion improving to 25%. Non-defense/export contribute 10–12% of revenue.

JSWSTEEL – JSW Steel – Q4 FY26 Earnings Call – 14-May-26

JSW Steel’s topline grows 10–14% CAGR (demand + capacity), bottomline leverages operating leverage + deleveraging, while margins remain resilient (18–22%) but sensitive to raw material costs and execution risks.

1–2 minutes

Also see: JSWSTEEL – JSW Steel – Q4 FY26 Financial Results – 14-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Key Variables: Domestic demand grows 7–9% (FY27), capex execution on track, coking coal costs stabilize at +$12–15/tonne.
Outcome: Revenue CAGR ~10%, EBITDA margins sustain at 18–20%, net debt/EBITDA <2.5x. 62M tonnes capacity by FY32 supports market share gains in flat steel. JV contributions (16M tonnes) accelerate growth without overleveraging.

MARUTI – Maruti Suzuki India – Q4 FY26 Earnings Call – 28-Apr-26

Maruti Suzuki’s topline growth hinges on capacity execution and macro stability; margins depend on commodity/FX normalization; EPS sensitivity to MTM losses and EV scaling.

1–2 minutes

Also see: MARUTI – Maruti Suzuki India – Q4 FY26 Financial Results – 28-Apr-26

3-Scenario Framework

📊 Base Case (50% Probability)

Conflict de-escalates by H2 FY27, commodity costs normalize (+50bps tailwind). Capacity additions on track, enabling +10% volume growth. EV sales scale to 50K units with Gujarat Line 4 ramp-up. EBIT margin stabilizes at 8.5–9%, EPS grows 5–8% on INR140B capex execution.

HINDALCO – Hindalco Industries – Q4 FY26 Financial Results – 22-May-26

Hindalco’s FY26 delivered ~10% pre‑exceptional earnings growth on 15% revenue jump, but debt rose ~56%, inventory ballooned 55%, and FCF turned negative amid capex bets. Novelis EBITDA/tonne recovery is the swing factor; FY26 is a transition year — watch Novelis margins, inventory normalization, and OCF recovery for re‑rating.

1–2 minutes

🔍 Observations

Topline

Consolidated revenue surged 15.3% YoY (₹2,38,496 Cr → ₹2,74,944 Cr), with Q4FY26 alone jumping 20.4% YoY (₹64,890 Cr → ₹78,133 Cr) — broadest quarterly run-rate in recent history.
Copper segment drove outsized topline contribution, growing 27.7% YoY (₹54,703 Cr → ₹69,838 Cr); Aluminium downstream accelerated 24.3% YoY (₹12,819 Cr → ₹15,938 Cr).
Novelis, the largest segment at 59% of revenue, grew a modest 12.3% YoY (₹1,45,068 Cr → ₹1,62,882 Cr) — volume/mix, not commodity tailwinds, likely driving it.

Bottomline

Reported PAT declined 16.3% YoY (₹16,002 Cr → ₹13,391 Cr), distorted entirely by exceptional charges of ₹6,963 Cr in FY26 vs. ₹879 Cr in FY25.
Pre-exceptional PBT grew 9.7% YoY (₹23,216 Cr → ₹25,459 Cr), confirming underlying earnings power is intact and expanding.
EPS (basic) compressed to ₹60.31 from ₹72.05 — optically weak, but exceptional-item-driven; core trajectory is positive.

Margins

Segment EBITDA expanded to ₹37,217 Cr from ₹35,162 Cr (+5.8% YoY); consolidated EBITDA (segment results + unallocable, pre-finance/D&A) at ₹38,097 Cr vs. ₹35,496 Cr (+7.3% YoY).
EBITDA margin on revenue from operations: 38,097 / 2,74,944 = 13.9% vs. 35,496 / 2,38,496 = 14.9% — 100 bps compression YoY, partly attributable to Copper’s lower-margin revenue mix growing fastest.
Aluminium upstream segment result improved to ₹18,884 Cr from ₹16,262 Cr (+16.1% YoY) — the highest-margin segment delivering the best absolute growth.

Growth Trajectory

Revenue CAGR implied over two years is healthy, but working capital consumption is accelerating disproportionately — a structural flag for FY27 free cash flow visibility.
Aluminium downstream, though small, grew 54.5% in segment results (₹633 Cr → ₹978 Cr) — early signs of downstream value-add monetisation.
Novelis segment result fell 4.6% YoY (₹15,242 Cr → ₹14,546 Cr) despite revenue growth — margin dilution at the most important subsidiary warrants monitoring.

EICHERMOT – Eicher Motors – Q4 FY26 Financial Results – 22-May-26

Eicher Motors’ FY26 delivered 24% revenue growth, ₹3,530 Cr FCF, near‑zero leverage, and VECV JV momentum. Risks: 150 bps PAT margin compression and Q4 revenue stall. Re‑rating now hinges on margin leverage from new platforms and global scale‑up; treasury earnings floor strong but RE must grow without dilution.

1–2 minutes

🔍 Observations

Topline

Revenue from operations crossed ₹23,408 Cr in FY26 vs ₹18,870 Cr in FY25 — 24.0% YoY growth, driven by Royal Enfield volume expansion and premiumisation
Q4FY26 revenue at ₹6,080 Cr vs ₹5,241 Cr in Q4FY25 — 16.0% YoY growth; sequentially flat vs Q3FY26 (₹6,114 Cr)
Other income (investment returns) rose to ₹1,487 Cr in FY26 from ₹1,305 Cr — meaningful contributor given the large treasury corpus

Bottomline

PAT grew 16.5% YoY to ₹5,515 Cr (FY26) from ₹4,734 Cr (FY25); Q4FY26 PAT at ₹1,520 Cr, up 11.6% vs Q4FY25 (₹1,362 Cr)
JV profit contribution (VECV) rose to ₹798 Cr in FY26 from ₹700 Cr — 14.0% YoY; Q4FY26 VECV share surged to ₹323 Cr vs ₹248 Cr in Q4FY25
Basic EPS expanded to ₹201.09 in FY26 from ₹172.76 in FY25 — 16.4% YoY growth

Margins

FY26 EBITDA (PBT before JV + D&A + Finance costs): ₹6,359.70 + ₹840.37 + ₹71.53 = ₹7,271.60 Cr on revenue of ₹23,408 Cr → EBITDA margin ~31.1% vs ~30.7% in FY25 (₹5,233.26 + ₹729.33 + ₹54.34 = ₹6,016.93 Cr / ₹18,870 Cr) — marginal expansion
Net profit margin (PAT / Revenue from ops): 5,515 / 23,408 = 23.6% vs 4,734 / 18,870 = 25.1% in FY25 — 150bps compression, partly from higher tax (effective rate rose from 20.2% to 22.3%)
Raw material + traded goods as % of revenue: (12,502 + 835 − 270) / 23,408 = 55.4% vs (9,953 + 507 − 164) / 18,870 = 54.8% — modest input cost inflation absorbed

Growth Trajectory

Revenue CAGR at 24% for FY26 points to strong demand; sequential flatness in Q4 warrants watching for volume plateau
PAT growth (16.5%) lagging revenue growth (24.0%) signals operating leverage not fully flowing through — cost base scaling faster than topline
VECV’s improving profit trajectory (14% YoY) adds earnings resilience via non-motorcycle diversification

SUNPHARMA – Sun Pharmaceutical Industries – Q4 FY26 Financial Results – 22-May-26

Sun Pharma’s FY26 delivered 11% topline growth with ~31.5% EBITDA margins, specialty pivot sustaining quality. PAT up 5% understates strength; underlying trajectory solid. Re‑rating hinges on specialty‑led margin inflection toward 34–35%. Risks: faster opex growth, acquisition integration, intangibles spike, and receivables build.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 11.2% YoY (₹525,784 Mn → ₹584,620 Mn), driven by both domestic formulations and specialty/global generic expansion.
Q4FY26 revenue of ₹146,118 Mn grew 12.8% YoY vs Q4FY25 (₹129,588 Mn), though declined 5.9% QoQ from Q3FY26’s ₹155,205 Mn — seasonal softness, not structural.
Other operating revenues fell sharply (₹5,372 Mn → ₹2,419 Mn YoY), a ₹2,953 Mn headwind to topline largely absorbed by core revenue momentum.

Bottomline

Reported PAT grew 5.0% YoY (₹109,290 Mn → ₹114,794 Mn); adjusted for ₹13,075 Mn of exceptional items in FY26 vs ₹6,779 Mn in FY25, underlying PAT growth is broadly similar.
Tax outflow surged — effective tax rate on reported PBT rose from ~17.4% to ~26.0% — compressing PAT despite strong EBIT growth; a large one-off deferred tax reversal benefited FY25.
EPS grew modestly from ₹45.6 to ₹47.8 (basic), with no dilution — share count flat at ~2,399 Mn shares.

Margins

EBITDA (PBT before exceptional + Finance costs + D&A): FY26 = ₹151,189 + ₹3,389 + ₹29,379 = ₹183,957 Mn on revenue of ₹584,620 Mn → EBITDA margin ~31.5% vs FY25: ₹137,521 + ₹2,314 + ₹25,754 = ₹165,589 Mn on ₹525,784 Mn → 31.5%. Margins held flat despite R&D intensity rising.
Net profit margin: ₹114,794 / ₹584,620 = 19.6% vs ₹109,290 / ₹525,784 = 20.8% — 120 bps compression, driven entirely by tax normalisation.
R&D spend rose to ₹34,741 Mn (5.9% of revenue) vs ₹31,542 Mn (6.0%) — pipeline investment sustained without margin sacrifice.

Growth Trajectory

Three-year revenue compound implied by 11.2% topline growth and consistent specialty mix shift signals durable mid-teens USD revenue CAGR in global markets.
Employee costs grew 14.5% YoY (₹99,731 Mn → ₹114,189 Mn), outpacing revenue — talent investment for specialty scaling, but warrants monitoring.
Other expenses grew 13.3% YoY (₹167,718 Mn → ₹190,083 Mn) — faster than revenue, suggesting operating leverage yet to fully materialise.

MAXHEALTH – Max Healthcare Institute – Q4 FY26 Financial Results – 21-May-26

Max Healthcare’s FY26 delivered 19% revenue and 34% PAT growth on ₹700 Cr+ base, confirming leverage in motion. Risks: near‑zero FCF and deteriorating receivables. FY27 re‑rating hinges on receivable discipline and debt‑to‑EBITDA as capex peaks; margin expansion and OCF strength keep structural story intact.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 19.1% YoY (₹7,02,846L → ₹8,37,345L), compounding on a large base — scale is not diluting growth velocity.
Q4FY26 revenue at ₹2,14,289L grew 12.2% YoY (vs ₹1,90,974L Q4FY25) and 3.6% QoQ — sequential momentum intact.
No segment data provided, but the pace of capacity addition (PPE up ₹1,49,712L YoY) signals the topline engine is being actively fuelled.

Bottomline

PAT grew 34.1% YoY (₹1,07,588L → ₹1,44,241L) — bottomline growing nearly 1.8x faster than revenue, confirming strong operating leverage.
Effective tax rate dropped sharply: 23.5% in FY26 vs 23.5% in FY25 headline-level, but FY25 included a deferred tax credit (₹562L) vs FY26 deferred charge (₹2,186L), masking an underlying cash tax improvement.
Q4FY26 PAT at ₹34,222L grew 7.3% YoY (vs ₹31,900L Q4FY25) — solid, though Q4FY25 had a higher current tax outflow (₹7,213L vs ₹5,858L), flattering the comparison.

Margins

EBITDA proxy (PBT before exceptional + D&A + Finance costs): FY26 = ₹1,72,382L + ₹44,653L + ₹23,510L = ₹2,40,545L on revenue of ₹8,37,345L → EBITDA margin ~28.7% vs FY25: (₹1,48,000L + ₹35,942L + ₹16,502L) / ₹7,02,846L = ₹2,00,444L → ~28.5% — margins essentially flat despite revenue scale-up.
Net profit margin: ₹1,44,241L / ₹8,37,345L = 17.2% vs ₹1,07,588L / ₹7,02,846L = 15.3% — 190bps expansion, driven by operating leverage on fixed costs.
Finance costs surged 42.5% YoY (₹16,502L → ₹23,510L), partially offsetting operating gains; bears watching as debt expands with capex.

Growth Trajectory

Revenue CAGR implied over FY25–26 at 19.1% on a ₹700Cr+ base is exceptional for a hospital network — pricing power + volume both contributing.
PAT growing at 34% with EBITDA flat suggests the leverage point is below EBITDA: D&A and finance costs are scaling, but PBT-to-PAT conversion is improving.
Capacity buildout (CWIP conversion + fresh PPE additions) suggests FY27 will test whether new beds can ramp revenues fast enough to sustain margin trajectory.

ITC – ITC Limited – Q4 FY26 Financial Results – 21-May-26

ITC’s FY26 delivered steady 5–10% growth, anchored by ~55% EBIT margins in cigarettes and near‑full OCF conversion. FMCG‑Others profitability is improving but still sub‑10%; Paperboards and Agri remain low‑margin. Re‑rating hinges on FMCG margin inflection, while cigarette margin compression makes ITC a yield‑focused compounder.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 10.2% YoY (₹81,613 Cr → ₹89,913 Cr), driven by cigarettes segment surging 13.1% YoY (₹35,894 Cr → ₹40,601 Cr) and FMCG-Others up 10.5%.
Q4FY26 gross revenue jumped 17.1% YoY (₹20,176 Cr → ₹23,626 Cr), the strongest quarterly print of the year — partly aided by excise duty reclassification inflating reported numbers.
Agri business grew modestly at 3.1% YoY (₹20,164 Cr → ₹20,787 Cr); Paperboards at 4.1% — both segments remain subdued relative to FMCG.

Bottomline

Profit from continuing operations grew 4.9% YoY (₹20,036 Cr → ₹21,018 Cr); EPS from continuing ops rose from ₹15.78 to ₹16.52 — steady but unspectacular.
FY26 total PAT appears down sharply vs. FY25 (₹21,018 Cr vs. ₹35,052 Cr) only because FY25 included ₹15,016 Cr from discontinued hotel operations post-demerger — not a like-for-like comparison.
Exceptional items of ₹291.70 Cr in FY26 (nil in FY25) modestly dented reported PBT; pre-exceptional PBT grew 5.2% YoY (₹26,927 Cr → ₹28,325 Cr).

Margins

Segment EBIT margin for cigarettes: ₹22,246 Cr on ₹40,601 Cr revenue = 54.8% — essentially flat vs. FY25’s 58.8% (₹21,091 Cr / ₹35,894 Cr); slight compression despite volume-led growth.
FMCG-Others segment results improved: ₹1,812 Cr on ₹24,322 Cr = 7.4% margin vs. 7.2% in FY25 — incremental but directionally positive.
Other income declined 4.1% YoY (₹2,530 Cr → ₹2,426 Cr), partly offsetting operating gains; reflects lower treasury yields or reduced investible surplus post-demerger.

Growth Trajectory

Pre-exceptional PBT 5-yr CAGR implied by this single-year step (FY25→FY26): +5.2% — modest for a cash-generative quasi-monopoly.
Associates & JV profit contribution surged to ₹377 Cr vs. ₹110 Cr in FY25 — partially reflecting post-demerger equity-accounting of hotel business.
FMCG-Others continues its multi-year profitability improvement arc; at 7.4% EBIT margin, still well below cigarettes’ ~55% — long runway but slow burn.